Compare StocksBAC vs MRNA

Bank of America Corporation (BAC) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?

As of 2026-06-19, BAC is undervalued at $56, with a DCF intrinsic value of $133 and a margin of safety of 58%. MRNA is overvalued at $64, with an intrinsic value of $6 and a margin of safety of -963%. Of the two, BAC has the wider margin of safety.

BAC
Bank of America Corporation
$56.20
VS
MRNA
Moderna, Inc.
$63.96

Rewards

BAC
  • Bank of America Corporation scores 100/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
MRNA

    Risks

    BAC
    • Gross margin of 0.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Altman Z-Score of 0.22 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

    Key Valuation Metrics

    Learn more →
    BAC
    MRNA
    Valuation
    N/A
    Free Cash Flow
    $-20.00M
    N/A
    FCF Yield
    -0.08%
    13.95
    Trailing P/E
    N/A
    11.13
    Forward P/E
    -15.21
    Quality & Moat
    3.89%
    ROIC
    -26.47%
    10.64%
    ROE
    -36.56%
    0.00%
    Gross Margin
    -69.89%
    1.02
    PEG Ratio
    N/A
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    Net cash
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    N/A
    1.97%
    Dividend Yield
    0.00%
    BAC: 4Ties: 1MRNA: 1
    BACMRNA

    Historical Fundamentals

    Learn more →
    BAC

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    BAC
    $2.37
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $55.63B
    Δ Market Cap
    +$131.83B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    BAC
    57.9% Margin of Safety
    Price is 57.9% below estimated fair value
    Current Price: $56.20
    Fair Value: $133.45
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    MRNA
    962.8% Overvalued
    Price is 962.8% above estimated fair value
    Current Price: $63.96
    Fair Value: $6.02
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    BAC

    Requires positive FCF to compute implied growth rate.

    MRNA

    Requires positive FCF to compute implied growth rate.

    Economic Moat Score

    Learn more →
    BAC
    100/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat driven primarily by revenue predictability. Reinvestment Efficiency is the area most vulnerable to competitive pressure.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    BAC
    -2.31
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    BAC
    Insiders 7.3%Institutions 70.6%Retail & Other 22.0%
    No. of Institutional Holders4,373
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    MRNA
    Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
    No. of Institutional Holders1,044
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    BAC
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    BAC
    0
    Sells (3M)
    5
    Sells (12M)
    Total value (12M): $20.17M
    MENSAH BERNARD AMPONSAH
    Officer
    $4.41M
    @ $46.94 · 2026-03-12
    SCRIVENER THOMAS M
    Officer
    $2.49M
    @ $49.82 · 2026-03-05
    BRONSTEIN SHERI B
    Officer
    $2.99M
    @ $49.91 · 2026-03-05
    ATHANASIA DEAN C
    President
    $6.86M
    @ $50.21 · 2026-03-03
    BORTHWICK ALASTAIR M.
    Chief Financial Officer
    $3.42M
    @ $50.24 · 2026-02-27
    MENSAH BERNARD AMPONSAH
    Officer
    $3.66M
    @ $39.80 · 2024-08-27
    HANS LINDSAY D
    Officer
    $402,410
    @ $36.91 · 2024-08-05
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    MRNA
    3
    Sells (3M)
    6
    Sells (12M)
    Total value (12M): $11.57M
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    AFEYAN NOUBAR BOGHOS
    Director
    $1.80M
    @ $119.96 · 2024-07-31
    AFEYAN NOUBAR BOGHOS
    Director
    $1.77M
    @ $117.80 · 2024-07-24
    AFEYAN NOUBAR BOGHOS
    Director
    $1.84M
    @ $122.84 · 2024-07-17
    HOGE STEPHEN
    President
    $1.82M
    @ $121.12 · 2024-07-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.76M
    @ $117.08 · 2024-07-10
    MOCK JAMES M
    Chief Financial Officer
    $81,465
    @ $118.24 · 2024-07-08
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.22 · 2024-06-26
    AFEYAN NOUBAR BOGHOS
    Director
    $2.00M
    @ $133.57 · 2024-06-18
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    BAC
    FearGreed
    😏Greed(74/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    MRNA
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    BAC
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (74)
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    View BAC Full AnalysisView MRNA Full Analysis

    Frequently Asked Questions: BAC vs MRNA

    Is Bank of America Corporation or Moderna, Inc. more undervalued in 2026?

    Based on our discounted cash flow model, BAC trades at a 57.9% margin of safety (intrinsic value $133 vs. price $56), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

    Which stock has a wider economic moat, Bank of America Corporation or Moderna, Inc.?

    BAC scores 100/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Bank of America Corporation in financial distress?

    BAC's Altman Z-Score of 0.2 places it in the Distress zone, signaling elevated bankruptcy risk. MRNA scores 2.5 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which stock has higher return on invested capital, Bank of America Corporation or Moderna, Inc.?

    BAC earns 3.9% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    BAC vs MRNA: Which Is the Better Buy in 2026? | SafetyMargin.io